Available to mentor
Dr. Heth joined the faculty at the University of Michigan Department of Neurosurgery in 2003. He was born in Iowa and primarily grew up in Iowa City. He attended the Johns Hopkins University and graduated with an undergraduate degree in Biomedical Engineering. He went to the University of Iowa for medical school and then residency. After spending a year in fellowship training with Osama Al-Mefty, MD, a pioneer in the field of skull base neurosurgery, Dr. Heth joined the faculty in 2003. He specializes in brain tumor surgery with particular interests in brain metastasis from systemic cancers, the effects of radiation treatment on the brain and brain metastasis, meningiomas, and skull base tumors. He has developed a strong interest in education and is very involved in medical student education, some specialized undergraduate programs, and residency training.
-
FellowshipUniversity of Arkansas for Medical Sciences, Neurosurgery, 2003
Brain metastasis and radiation necrosis/treatment effects on the CNS
Educational initiatives in medical students and undergraduate students, particularly "first in family" students
-
Serhan HA, Bao L, Cheng X, Qin Z, Liu C-J, Heth JA, Udager AM, Soellner MB, Merajver SD, Morikawa A, Merrill NM. NPJ Breast Cancer, 2024 Jun 10; 10 (1): 43Journal ArticleTargeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion.
DOI:10.1038/s41523-024-00656-0 PMID: 38858374 -
Morikawa A, Rastogi T, Ulintz P, Serhan H, Nieblas-Bedolla E, Heth J, Cheng X, Bao L, Udager AM, Soellner M, Merrill N, Merajver SD. Journal of Clinical Oncology, 2024 Aug 10; 42 (23_suppl): 28 - 28.Proceeding / Abstract / PosterExamining molecular landscape and drug sensitivity profiles of patient-derived xenografts from resected brain metastases.
DOI:10.1200/jco.2024.42.23_suppl.28 -
Umemura Y, Clarke N, Al-Holou W, Elaimy A, Scott A, Leung D, Kim M, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Chin Clin Oncol, 2024 Aug; 13 (Suppl 1): AB036Journal ArticleAB036. Targeting glioblastoma de-novo purine metabolism to overcome chemoradiation resistance: an interim result of phase 0/1 clinical trial in newly diagnosed and recurrent glioblastoma.
DOI:10.21037/cco-24-ab036 PMID: 39295354 -
Heth J. 2024 May 19;PresentationEvolution of Standardized Letters of Evaluation: Progress?
-
Scott AJ, O'Brien A, Zhou W, Xu J, Palavalasa S, Kothari AU, Wilder-Romans K, Zhang L, Andren AC, Chandrasekaran S, Heth J, Umemura Y, Qi N, Lawrence TS, Al-Holou WN, Lyssiotis CA, Wahl DR. Cancer Research, 2024 Mar 4; 84 (5_Supplement_1): b051 - b051.Journal ArticleAbstract B051: DNA damage signaling activates GTP synthesis to promote glioblastoma treatment resistance
DOI:10.1158/1538-7445.brain23-b051 -
Bowden SG, Tan H, Rothbaum MG, Cook SH, Hanft S, Heth J, Morgenstern PF, Mullin JP, Orina JN, Wilson JL, Winer JL, Wolfe SQ, Chambless LB, Selden NR. J Neurosurg, 2023 Dec 1; 139 (6): 1748 - 1756.Journal ArticleMilestones for neurosurgery sub-interns: a novel evaluation tool to quantitatively differentiate residency applicants.
DOI:10.3171/2023.3.JNS23259 PMID: 37148230 -
Wadden J, John V, Niculcea M, Kong S, Aittaleb R, Cartaxo R, Verbal K, Bruzek A, Magge S, Yadavilli S, Erez N, Furth N, Shema E, Marapudi N, Heth J, Al-holou W, Garton H, Nazarian J, Koschmann C. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v17 - v18.Journal ArticleBIOM-58. ZERO-WASTE MOLECULAR DIAGNOSTICS FROM BIOPSY NEEDLE WASHES
DOI:10.1093/neuonc/noad179.0069 -
Umemura Y, Al-Holou W, Elaimy A, Scott AJ, Leung D, Clarke N, Kim MM, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v90 - v90.Proceeding / Abstract / PosterCTNI-61. MYCOPHENOLATE MOFETIL INHIBITS GLIOBLASTOMA PURINE METABOLISM IN HUMANS: AN INTERIM RESULT OF PHASE 0/1 CLINICAL TRIAL TO OVERCOME TREATMENT RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
DOI:10.1093/neuonc/noad179.0343